SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about revised press release

16 Dec 2023 Evaluate
Cipla has informed that further to the press release submitted by the Company on 10th December 2023, It was brought to attention by US FDA that there was information in its risk assessment that was not pertinent to this product. As a result the company reissued a revised press release Voluntary Nationwide Recall of one lot of Vigabatrin for Oral Solution, USP 500mg due to leaking sachets by InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company in USA.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×